Payment overview · 2025
General Payments
$269.60
10 reported records · 7 companies
Healthcare provider profile · identity verified
Jung Moon Bae, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1124119805
Verified facts
What the public records show
CMS Open Payments records show Jung Moon Bae, M.D. received $269.60 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 46.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 466 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 282 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.17 | 46.4% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.61 | 10.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.42 | 10.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.24 | 9.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.72 | 8.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.23 | 7.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.21 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $269.60 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $125.17 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $125.17 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 466 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 282 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 329 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
466 | 116 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
329 | 66 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
282 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1442 | 284 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1148 | 209 |
| Vascepa | Icosapent Ethyl | 880 | 140 |
| Montelukast Sodium | Montelukast Sodium | 782 | 125 |
| Losartan Potassium | Losartan Potassium | 699 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 676 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 610 | 94 |
| Simvastatin | Simvastatin | 564 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 546 | 100 |
| Memantine Hcl Er | Memantine Hcl | 540 | 86 |
| Azithromycin | Azithromycin | 537 | 268 |
| Creon | Lipase/Protease/Amylase | 466 | 116 |
| Metformin Hcl Er | Metformin Hcl | 461 | 82 |
| Gabapentin | Gabapentin | 437 | 89 |
| Raloxifene Hcl | Raloxifene Hcl | 436 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 427 | 83 |
| Celecoxib | Celecoxib | 420 | 82 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 415 | 73 |
| Meloxicam | Meloxicam | 398 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 386 | 67 |
| Omeprazole | Omeprazole | 385 | 85 |
| Donepezil Hcl | Donepezil Hcl | 381 | 49 |
| Linzess | Linaclotide | 329 | 66 |
| Alendronate Sodium | Alendronate Sodium | 325 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 311 | 47 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 308 | 41 |
| Furosemide | Furosemide | 285 | 63 |
| Jardiance | Empagliflozin | 282 | 44 |
| Mirtazapine | Mirtazapine | 279 | 43 |
| Tramadol Hcl | Tramadol Hcl | 278 | 70 |
| Sertraline Hcl | Sertraline Hcl | 272 | 55 |
| Trazodone Hcl | Trazodone Hcl | 268 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 263 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 240 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 235 | 91 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 219 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 208 | 50 |
| Tradjenta | Linagliptin | 207 | 32 |
| Metformin Hcl | Metformin Hcl | 203 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 52 |
| Finasteride | Finasteride | 184 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 52 |
| Potassium Chloride | Potassium Chloride | 167 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 160 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 156 | 45 |
| Ezetimibe | Ezetimibe | 150 | 25 |
| Pregabalin | Pregabalin | 148 | 24 |
| Levofloxacin | Levofloxacin | 147 | 99 |
| Januvia | Sitagliptin Phosphate | 146 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 27 |
| Mometasone Furoate | Mometasone Furoate | 135 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 42 |
| Famotidine | Famotidine | 133 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 131 | 26 |
| Myrbetriq | Mirabegron | 130 | 18 |
| Ciclopirox | Ciclopirox Olamine | 127 | 50 |
| Jentadueto | Linagliptin/Metformin Hcl | 124 | 20 |
| Atenolol | Atenolol | 123 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 123 | 29 |
| Memantine Hcl | Memantine Hcl | 122 | 27 |
| Ketoconazole | Ketoconazole | 121 | 28 |
| Ibuprofen | Ibuprofen | 113 | 52 |
| Allopurinol | Allopurinol | 111 | 16 |
| Megestrol Acetate | Megestrol Acetate | 111 | 33 |
| Glipizide | Glipizide | 110 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 109 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 109 | 45 |
| Xarelto | Rivaroxaban | 108 | 15 |
| Lidocaine | Lidocaine | 104 | 18 |
| Lorazepam | Lorazepam | 104 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 27 |
| Baclofen | Baclofen | 95 | 25 |
| Temazepam | Temazepam | 95 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 93 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 92 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 92 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 63 |
| Carvedilol | Carvedilol | 89 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 87 | 55 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 12 |
| Spironolactone | Spironolactone | 86 | 21 |
| Alprazolam | Alprazolam | 85 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 15 |
| Nifedipine Er | Nifedipine | 85 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 84 | 14 |
| Mupirocin | Mupirocin | 83 | 28 |
| Eliquis | Apixaban | 80 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 78 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 75 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 18 |
| Procto-Med Hc | Hydrocortisone | 70 | 22 |
| Sucralfate | Sucralfate | 69 | 13 |
| Glipizide Er | Glipizide | 67 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 56 |
| Meclizine Hcl | Meclizine Hcl | 65 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 62 | 12 |
| Benazepril Hcl | Benazepril Hcl | 61 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 59 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 59 | 17 |
| Trulicity | Dulaglutide | 58 | suppressed |
| Cyclosporine | Cyclosporine | 57 | suppressed |
| Valsartan | Valsartan | 56 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | suppressed |
| Hydrocortisone | Hydrocortisone | 55 | 18 |
| Gemtesa | Vibegron | 53 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 11 |
| Bumetanide | Bumetanide | 46 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Ursodiol | Ursodiol | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 32 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Nateglinide | Nateglinide | 43 | suppressed |
| Restasis | Cyclosporine | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 27 |
| Kerendia | Finerenone | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 20 |
| Irbesartan | Irbesartan | 37 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 16 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 11 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 30 | suppressed |
| Fluocinonide | Fluocinonide | 30 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 18 |
| Single Use Swab | Alcohol Antiseptic Pads | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Entecavir | Entecavir | 24 | suppressed |
| Lisinopril | Lisinopril | 24 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 22 | suppressed |
| Dexilant | Dexlansoprazole | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Zenpep | Lipase/Protease/Amylase | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 11 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 15 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $269.60 · 10 records | ABBVIE INC. | CREON, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LINZESS, Ozempic, Rybelsus, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error